Key result
Aspirin compared to placebo in post-myocardial infarction patients did not reduce all-cause mortality using standard logrank or log.
Why the study?
Does aspirin reduce all-cause mortality in post-myocardial infarction patients?
Meta-Analysis (n=10,703)
Placebo-controlled
Randomized
Yes
Does aspirin reduce all-cause mortality in post-myocardial infarction patients?
A meta-analysis of six trials of aspirin in post-MI patients showed no definitive statistically significant reduction in all-cause mortality using standard meta-analytic methods.
Answers are grounded in this paper and cite their sources.
Aspirin does not significantly reduce all-cause mortality post-MI; challenges prior meta-analyses and warrants methodologic re-evaluation.
Data from six randomized, placebo-controlled clinical trials of aspirin, involving a total of 10,703 post-myocardial infarction patients, have been compared and combined. An apparent heterogeneity of findings among the six trials with respect to all-cause mortality is noted (P = 0.08). The reasons for this heterogeneity are explored. Two common methods of combining the results of several trials--the logrank and the log odds ratio methods--yield two-sided P-values of 0.112 and 0.110, respectively, for the aspirin-placebo effect on all-cause mortality. Alternative statistical methods of combining the results of the six trials give two-sided P-values ranging from 0.017 to 0.487.
No takes yet. Share an insight, caveat, or question.
Paul L. Canner (1987) conducted a meta-analysis in Post-myocardial infarction (n=10,703). Aspirin vs. Placebo was evaluated on All-cause mortality (p=0.110 to 0.112). Aspirin compared to placebo in post-myocardial infarction patients did not reduce all-cause mortality using standard logrank or log.
Synapse has enriched 10 related papers. Consider them for comparative context: